Literature DB >> 14767518

Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells.

Tao Bai1, Tetsuji Tanaka, Kazunori Yukawa, Masanobu Maeda, Naohiko Umesaki.   

Abstract

The expression of the death-associated protein kinase (DAPK) protein and promoter methylation in 11 human uterine and ovarian carcinoma cell lines originally established from histopathologically-different carcinoma tissues were examined to investigate the relationship between DAPK and carcinogenesis in female reproductive tissues. The 11 cell lines included three cervical carcinomas, three endometrial carcinomas and five ovarian carcinomas. Western blot analysis showed no detectable expression of DAPK protein in 4 cell lines (ME180, HOKUG, MCAS and OVK-18) while moderate levels of DAPK protein were readily detected in normal human endometrium, and normal murine uterus and ovary. Methylation-specific PCR of the 11 cell lines revealed that 5 carcinoma cell lines (ME180, HOKUG, MCAS, OVK-18 and HEC-1) expressed hypermethylated promoters in the DAPK genes, while DAPK promoters in the other 6 carcinoma cell lines remained unmethylated. These results indicate that DAPK protein expression is reduced or silenced in some human uterine and ovarian carcinoma cells by methylation of the DAPK gene promoter region. Therefore, reduced DAPK expression and methylation of the DAPK promoter may be involved in carcinogenesis of human uterine and ovarian tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767518

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  DNA hypermethylation profiles in squamous cell carcinoma of the vulva.

Authors:  Josena K Stephen; Kang Mei Chen; Misa Raitanen; Seija Grénman; Maria J Worsham
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

2.  Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation.

Authors:  Yijun Jin; Emily K Blue; Patricia J Gallagher
Journal:  J Biol Chem       Date:  2006-10-20       Impact factor: 5.157

3.  Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.

Authors:  Tetsuji Tanaka; Tao Bai; Saori Toujima; Tomoko Utsunomiya; Toshihide Matsuoka; Aya Kobayashi; Madoka Yamamoto; Noriyuki Sasaki; Yuko Tanizaki; Hirotoshi Utsunomiya; Junko Tanaka; Kazunori Yukawa
Journal:  Oncol Rep       Date:  2012-01-11       Impact factor: 3.906

Review 4.  Epigenetic regulation of cancer-associated genes in ovarian cancer.

Authors:  Mi Jeong Kwon; Young Kee Shin
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

Review 5.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

6.  Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium.

Authors:  Tomoe Nomura; Tomomitsu Tahara; Hisakazu Shiroeda; Takahiro Minato; Yasuhiro Matsue; Ranji Hayashi; Kazuhiro Matsunaga; Toshimi Otsuka; Masakatsu Nakamura; Nobuyuki Toshikuni; Tomoyuki Shibata; Tomiyasu Arisawa
Journal:  BMC Gastroenterol       Date:  2013-01-02       Impact factor: 3.067

7.  Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China.

Authors:  Mei Ye; Bing Xia; Qiusha Guo; Feng Zhou; Xiaolian Zhang
Journal:  BMC Cancer       Date:  2007-07-03       Impact factor: 4.430

8.  DNA methylation and apoptosis resistance in cancer cells.

Authors:  Eric Hervouet; Mathilde Cheray; François Marie Vallette; Pierre-François Cartron
Journal:  Cells       Date:  2013-07-18       Impact factor: 6.600

9.  MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.

Authors:  Jing Zhang; Lei Liu; Yunyan Sun; Jiandong Xiang; Dongmei Zhou; Li Wang; Huali Xu; Xiaoming Yang; Na Du; Meng Zhang; Qin Yan; Xiaowei Xi
Journal:  Oncotarget       Date:  2016-05-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.